Pathophysiological role of guanylate-binding proteins in gastrointestinal diseases

World Journal of Gastroenterology

Volumn 22, Issue 28, 2016, Pages 6434-6443

  Britzen Laurent, Nathalie ^a   Herrmann, Christian ^b   Naschberger, Elisabeth ^a   Croner, Roland S ^a   Stürzl, Michael ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Colorectal carcinoma; Guanylate binding proteins; Inflammatory bowel diseases; Interferon

Indexed keywords

GAMMA INTERFERON; GUANINE NUCLEOTIDE BINDING PROTEIN; T LYMPHOCYTE RECEPTOR; GBP1 PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR;

ACTIN FILAMENT; APOPTOSIS; BLOOD VESSEL REACTIVITY; CANCER INHIBITION; CELL ACTIVATION; CELL ACTIVITY; CELL PROLIFERATION; CELLS BY BODY ANATOMY; COLON CARCINOGENESIS; COLON MUCOSA; COLORECTAL CARCINOMA; GASTROINTESTINAL DISEASE; HUMAN; IMMUNOREGULATION; INFLAMMATORY BOWEL DISEASE; INTESTINE EPITHELIUM CELL; INTESTINE FLORA; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR VASCULARIZATION; COLORECTAL TUMOR; IMMUNOLOGY; INTESTINE MUCOSA; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PROGNOSIS; TH1 CELL;

APOPTOSIS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; GTP-BINDING PROTEINS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERFERON-GAMMA; INTESTINAL MUCOSA; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RECEPTORS, ANTIGEN, T-CELL; TH1 CELLS;

EID: 84979502165     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i28.6434     Document Type: Review

References (76)

1. Ghosh A, Praefcke GJ, Renault L, Wittinghofer A, Herrmann C. How guanylate-binding proteins achieve assembly-stimulated processive cleavage of GTP to GMP. Nature 2006; 440: 101-104 [PMID: 16511497]
2. Vöpel T, Syguda A, Britzen-Laurent N, Kunzelmann S, Lüdemann MB, Dovengerds C, Stürzl M, Herrmann C. Mechanism of GTPaseactivity-induced self-assembly of human guanylate binding protein 1. J Mol Biol 2010; 400: 63-70 [PMID: 20450919]
3. Wehner M, Kunzelmann S, Herrmann C. The guanine cap of human guanylate-binding protein 1 is responsible for dimerization and selfactivation of GTP hydrolysis. FEBS J 2012; 279: 203-210 [PMID: 22059445 DOI: 10.1111/j.1742-4658.2011.08415.x]
4. Cheng YS, Colonno RJ, Yin FH. Interferon induction of fibroblast proteins with guanylate binding activity. J Biol Chem 1983; 258: 7746-7750 [PMID: 6305951]
5. Lubeseder-Martellato C, Guenzi E, Jörg A, Töpolt K, Naschberger E, Kremmer E, Zietz C, Tschachler E, Hutzler P, Schwemmle M, Matzen K, Grimm T, Ensoli B, Stürzl M. Guanylate-binding protein-1 expression is selectively induced by inflammatory cytokines and is an activation marker of endothelial cells during inflammatory diseases. Am J Pathol 2002; 161: 1749-1759 [PMID: 12414522]
6. Olszewski MA, Gray J, Vestal DJ. In silico genomic analysis of the human and murine guanylate-binding protein (GBP) gene clusters. J Interferon Cytokine Res 2006; 26: 328-352 [PMID: 16689661 DOI: 10.1089/jir.2006.26.328]
7. Degrandi D, Konermann C, Beuter-Gunia C, Kresse A, Würthner J, Kurig S, Beer S, Pfeffer K. Extensive characterization of IFNinduced GTPases mGBP1 to mGBP10 involved in host defense. J Immunol 2007; 179: 7729-7740 [PMID: 18025219]
8. Prakash B, Praefcke GJ, Renault L, Wittinghofer A, Herrmann C. Structure of human guanylate-binding protein 1 representing a unique class of GTP-binding proteins. Nature 2000; 403: 567-571 [PMID: 10676968]
9. Britzen-Laurent N, Bauer M, Berton V, Fischer N, Syguda A, Reipschläger S, Naschberger E, Herrmann C, Stürzl M. Intracellular trafficking of guanylate-binding proteins is regulated by heterodimerization in a hierarchical manner. PLoS One 2010; 5: e14246 [PMID: 21151871 DOI: 10.1371/journal.pone.0014246]
10. Praefcke GJ, Kloep S, Benscheid U, Lilie H, Prakash B, Herrmann C. Identification of residues in the human guanylate-binding protein 1 critical for nucleotide binding and cooperative GTP hydrolysis. J Mol Biol 2004; 344: 257-269 [PMID: 15504415]
11. Kunzelmann S, Praefcke GJ, Herrmann C. Transient kinetic investigation of GTP hydrolysis catalyzed by interferon-gammainduced hGBP1 (human guanylate binding protein 1). J Biol Chem 2006; 281: 28627-28635 [PMID: 16873363]
12. Rani A, Pandita E, Rahman S, Deep S, Sau AK. Insight into temperature dependence of GTPase activity in human guanylate binding protein-1. PLoS One 2012; 7: e40487 [PMID: 22859948 DOI: 10.1371/journal.pone.0040487]
13. Vöpel T, Kunzelmann S, Herrmann C. Nucleotide dependent cysteine reactivity of hGBP1 uncovers a domain movement during GTP hydrolysis. FEBS Lett 2009; 583: 1923-1927 [PMID: 19463820 DOI: 10.1016/j.febslet.2009.05.027]
14. Vöpel T, Hengstenberg CS, Peulen TO, Ajaj Y, Seidel CA, Herrmann C, Klare JP. Triphosphate induced dimerization of human guanylate binding protein 1 involves association of the C-terminal helices: a joint double electron-electron resonance and FRET study. Biochemistry 2014; 53: 4590-4600 [PMID: 24991938 DOI: 10.1021/bi500524u]
15. Britzen-Laurent N, Lipnik K, Ocker M, Naschberger E, Schellerer VS, Croner RS, Vieth M, Waldner M, Steinberg P, Hohenadl C, Stürzl M. GBP-1 acts as a tumor suppressor in colorectal cancer cells. Carcinogenesis 2013; 34: 153-162 [PMID: 23042300 DOI: 10.1093/carcin/bgs310]
16. Guenzi E, Töpolt K, Cornali E, Lubeseder-Martellato C, Jörg A, Matzen K, Zietz C, Kremmer E, Nappi F, Schwemmle M, Hohenadl C, Barillari G, Tschachler E, Monini P, Ensoli B, Stürzl M. The helical domain of GBP-1 mediates the inhibition of endothelial cell proliferation by inflammatory cytokines. EMBO J 2001; 20: 5568-5577 [PMID: 11598000]
17. Naschberger E, Wenzel J, Kretz CC, Herrmann M, Stürzl M, Kuhn A. Increased expression of guanylate binding protein-1 in lesional skin of patients with cutaneous lupus erythematosus. Exp Dermatol 2011; 20: 102-106 [PMID: 21121962 DOI: 10.1111/j.1600-0625.2010.01160.x]
18. MacMicking JD. Interferon-inducible effector mechanisms in cellautonomous immunity. Nat Rev Immunol 2012; 12: 367-382 [PMID: 22531325 DOI: 10.1038/nri3210]
19. Naschberger E, Croner RS, Merkel S, Dimmler A, Tripal P, Amann KU, Kremmer E, Brueckl WM, Papadopoulos T, Hohenadl C, Hohenberger W, Stürzl M. Angiostatic immune reaction in colorectal carcinoma: Impact on survival and perspectives for antiangiogenic therapy. Int J Cancer 2008; 123: 2120-2129 [PMID: 18697200 DOI: 10.1002/ijc.23764]
20. Schnoor M, Betanzos A, Weber DA, Parkos CA. Guanylate-binding protein-1 is expressed at tight junctions of intestinal epithelial cells in response to interferon-gamma and regulates barrier function through effects on apoptosis. Mucosal Immunol 2009; 2: 33-42 [PMID: 19079332]
21. Haep L, Britzen-Laurent N, Weber TG, Naschberger E, Schaefer A, Kremmer E, Foersch S, Vieth M, Scheuer W, Wirtz S, Waldner M, Stürzl M. Interferon Gamma Counteracts the Angiogenic Switch and Induces Vascular Permeability in Dextran Sulfate Sodium Colitis in Mice. Inflamm Bowel Dis 2015; 21: 2360-2371 [PMID: 26164664 DOI: 10.1097/MIB.0000000000000490]
22. Laghi L, Malesci A. Microsatellite instability and therapeutic consequences in colorectal cancer. Dig Dis 2012; 30: 304-309 [PMID: 22722556 DOI: 10.1159/000337003]
23. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009; 58: 90-96 [PMID: 18832519 DOI: 10.1136/gut.2008.155473]
24. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, Ostos LC, Lannon WA, Grotzinger C, Del Rio M, Lhermitte B, Olshen AB, Wiedenmann B, Cantley LC, Gray JW, Hanahan D. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 2013; 19: 619-625 [PMID: 23584089 DOI: 10.1038/nm.3175]
25. Sadanandam A, Wang X, de Sousa E Melo F, Gray JW, Vermeulen L, Hanahan D, Medema JP. Reconciliation of classification systems defining molecular subtypes of colorectal cancer: interrelationships and clinical implications. Cell Cycle 2014; 13: 353-357 [PMID: 24406433 DOI: 10.4161/cc.27769]
26. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagès F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-1964 [PMID: 17008531 DOI: 10.1126/science.1129139]
27. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH, Pagès F, Galon J. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011; 71: 1263-1271 [PMID: 21303976]
28. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12: 298-306 [PMID: 22419253]
29. Galon J, Pagès F, Marincola FM, Thurin M, Trinchieri G, Fox BA, Gajewski TF, Ascierto PA. The immune score as a new possible approach for the classification of cancer. J Transl Med 2012; 10: 1 [PMID: 22214470 DOI: 10.1186/1479-5876-10-1]
30. Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, Church SE, Lafontaine L, Fischer M, Fredriksen T, Sasso M, Bilocq AM, Kirilovsky A, Obenauf AC, Hamieh M, Berger A, Bruneval P, Tuech JJ, Sabourin JC, Le Pessot F, Mauillon J, Rafii A, Laurent-Puig P, Speicher MR, Trajanoski Z, Michel P, Sesboüe R, Frebourg T, Pagès F, Valge-Archer V, Latouche JB, Galon J. Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. Immunity 2016; 44: 698-711 [PMID: 26982367 DOI: 10.1016/j.immuni.2016.02.025]
31. Grenz S, Naschberger E, Merkel S, Britzen-Laurent N, Schaal U, Konrad A, Aigner M, Rau TT, Hartmann A, Croner RS, Hohenberger W, Stürzl M. IFN-?-driven intratumoral microenvironment exhibits superior prognostic effect compared with an IFN-?-driven microenvironment in patients with colon carcinoma. Am J Pathol 2013; 183: 1897-1909 [PMID: 24121019 DOI: 10.1016/j.ajpath.2013.08.025]
32. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337 [PMID: 22810696]
33. Carretero R, Wang E, Rodriguez AI, Reinboth J, Ascierto ML, Engle AM, Liu H, Camacho FM, Marincola FM, Garrido F, Cabrera T. Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferonmediated rejection genes. Int J Cancer 2012; 131: 387-395 [PMID: 21964766 DOI: 10.1002/ijc.26471]
34. Ascierto ML, Kmieciak M, Idowu MO, Manjili R, Zhao Y, Grimes M, Dumur C, Wang E, Ramakrishnan V, Wang XY, Bear HD, Marincola FM, Manjili MH. A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat 2012; 131: 871-880 [PMID: 21479927 DOI: 10.1007/s10549-011-1470-x]
35. Guimarães DP, Oliveira IM, de Moraes E, Paiva GR, Souza DM, Barnas C, Olmedo DB, Pinto CE, Faria PA, De Moura Gallo CV, Small IA, Ferreira CG, Hainaut P. Interferon-inducible guanylate binding protein (GBP)-2: a novel p53-regulated tumor marker in esophageal squamous cell carcinomas. Int J Cancer 2009; 124: 272-279 [PMID: 19003964 DOI: 10.1002/ijc.23944]
36. Godoy P, Cadenas C, Hellwig B, Marchan R, Stewart J, Reif R, Lohr M, Gehrmann M, Rahnenführer J, Schmidt M, Hengstler JG. Interferon-inducible guanylate binding protein (GBP2) is associated with better prognosis in breast cancer and indicates an efficient T cell response. Breast Cancer 2014; 21: 491-499 [PMID: 23001506 DOI: 10.1007/s12282-012-0404-8]
37. Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol 2014; 20: 91-99 [PMID: 24415861 DOI: 10.3748/wjg.v20.i1.91]
38. Wallace KL, Zheng LB, Kanazawa Y, Shih DQ. Immunopathology of inflammatory bowel disease. World J Gastroenterol 2014; 20: 6-21 [PMID: 24415853 DOI: 10.3748/wjg.v20.i1.6]
39. Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK. Role of cytokines in inflammatory bowel disease. World J Gastroenterol 2008; 14: 4280-4288 [PMID: 18666314]
40. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol 2014; 14: 329-342 [PMID: 24751956 DOI: 10.1038/nri3661]
41. Geremia A, Biancheri P, Allan P, Corazza GR, Di Sabatino A. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev 2014; 13: 3-10 [PMID: 23774107 DOI: 10.1016/j.autrev.2013.06.004]
42. Bouguen G, Chevaux JB, Peyrin-Biroulet L. Recent advances in cytokines: therapeutic implications for inflammatory bowel diseases. World J Gastroenterol 2011; 17: 547-556 [PMID: 21350703 DOI: 10.3748/wjg.v17.i5.547]
43. Capaldo CT, Beeman N, Hilgarth RS, Nava P, Louis NA, Naschberger E, Stürzl M, Parkos CA, Nusrat A. IFN-? and TNF-?-induced GBP-1 inhibits epithelial cell proliferation through suppression of ?-catenin/TCF signaling. Mucosal Immunol 2012; 5: 681-690 [PMID: 22692453]
44. Pammer J, Reinisch C, Birner P, Pogoda K, Sturzl M, Tschachler E. Interferon-alpha prevents apoptosis of endothelial cells after shortterm exposure but induces replicative senescence after continuous stimulation. Lab Invest 2006; 86: 997-1007 [PMID: 16894355 DOI: 10.1038/labinvest.3700461]
45. Naschberger E, Lubeseder-Martellato C, Meyer N, Gessner R, Kremmer E, Gessner A, Stürzl M. Human guanylate binding protein-1 is a secreted GTPase present in increased concentrations in the cerebrospinal fluid of patients with bacterial meningitis. Am J Pathol 2006; 169: 1088-1099 [PMID: 16936281]
46. Guenzi E, Töpolt K, Lubeseder-Martellato C, Jörg A, Naschberger E, Benelli R, Albini A, Stürzl M. The guanylate binding protein-1 GTPase controls the invasive and angiogenic capability of endothelial cells through inhibition of MMP-1 expression. EMBO J 2003; 22: 3772-3782 [PMID: 12881412]
47. Weinländer K, Naschberger E, Lehmann MH, Tripal P, Paster W, Stockinger H, Hohenadl C, Stürzl M. Guanylate binding protein-1 inhibits spreading and migration of endothelial cells through induction of integrin alpha4 expression. FASEB J 2008; 22: 4168-4178 [PMID: 18697840 DOI: 10.1096/fj.08-107524]
48. Balasubramanian S, Messmer-Blust AF, Jeyaratnam JA, Vestal DJ. Role of GTP binding, isoprenylation, and the C-terminal ?-helices in the inhibition of cell spreading by the interferon-induced GTPase, mouse guanylate-binding protein-2. J Interferon Cytokine Res 2011; 31: 291-298 [PMID: 20950129 DOI: 10.1089/jir.2010.0056]
49. Messmer-Blust AF, Balasubramanian S, Gorbacheva VY, Jeyaratnam JA, Vestal DJ. The interferon-gamma-induced murine guanylate-binding protein-2 inhibits rac activation during cell spreading on fibronectin and after platelet-derived growth factor treatment: role for phosphatidylinositol 3-kinase. Mol Biol Cell 2010; 21: 2514-2528 [PMID: 20505078]
50. Ostler N, Britzen-Laurent N, Liebl A, Naschberger E, Lochnit G, Ostler M, Forster F, Kunzelmann P, Ince S, Supper V, Praefcke GJ, Schubert DW, Stockinger H, Herrmann C, Stürzl M. Gamma interferon-induced guanylate binding protein 1 is a novel actin cytoskeleton remodeling factor. Mol Cell Biol 2014; 34: 196-209 [PMID: 24190970 DOI: 10.1128/MCB.00664-13]
51. Cromer WE, Mathis JM, Granger DN, Chaitanya GV, Alexander JS. Role of the endothelium in inflammatory bowel diseases. World J Gastroenterol 2011; 17: 578-593 [PMID: 21350707 DOI: 10.3748/wjg.v17.i5.578]
52. Danese S, Sans M, de la Motte C, Graziani C, West G, Phillips MH, Pola R, Rutella S, Willis J, Gasbarrini A, Fiocchi C. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology 2006; 130: 2060-2073 [PMID: 16762629 DOI: 10.1053/j.gastro.2006.03.054]
53. Cromer WE, Ganta CV, Patel M, Traylor J, Kevil CG, Alexander JS, Mathis JM. VEGF-A isoform modulation in an preclinical TNBS model of ulcerative colitis: protective effects of a VEGF164b therapy. J Transl Med 2013; 11: 207 [PMID: 24020796 DOI: 10.118 6/1479-5876-11-207]
54. Forster F, Paster W, Supper V, Schatzlmaier P, Sunzenauer S, Ostler N, Saliba A, Eckerstorfer P, Britzen-Laurent N, Schütz G, Schmid JA, Zlabinger GJ, Naschberger E, Stürzl M, Stockinger H. Guanylate binding protein 1-mediated interaction of T cell antigen receptor signaling with the cytoskeleton. J Immunol 2014; 192: 771-781 [PMID: 24337748 DOI: 10.4049/jimmunol.1300377]
55. Yu CJ, Chang KP, Chang YJ, Hsu CW, Liang Y, Yu JS, Chi LM, Chang YS, Wu CC. Identification of guanylate-binding protein 1 as a potential oral cancer marker involved in cell invasion using omics-based analysis. J Proteome Res 2011; 10: 3778-3788 [PMID: 21714544 DOI: 10.1021/pr2004133]
56. Lipnik K, Naschberger E, Gonin-Laurent N, Kodajova P, Petznek H, Rungaldier S, Astigiano S, Ferrini S, Stürzl M, Hohenadl C. Interferon gamma-induced human guanylate binding protein 1 inhibits mammary tumor growth in mice. Mol Med 2010; 16: 177-187 [PMID: 20454519 DOI: 10.2119/molmed.2009.00172]
57. Duan Z, Foster R, Brakora KA, Yusuf RZ, Seiden MV. GBP1 overexpression is associated with a paclitaxel resistance phenotype. Cancer Chemother Pharmacol 2006; 57: 25-33 [PMID: 16028104 DOI: 10.1007/s00280-005-0026-3]
58. De Donato M, Mariani M, Petrella L, Martinelli E, Zannoni GF, Vellone V, Ferrandina G, Shahabi S, Scambia G, Ferlini C. Class III ?-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer. J Cell Physiol 2012; 227: 1034-1041 [PMID: 21520077 DOI: 10.1002/jcp.22813]
59. Desarnaud F, Geck P, Parkin C, Carpinito G, Makarovskiy AN. Gene expression profiling of the androgen independent prostate cancer cells demonstrates complex mechanisms mediating resistance to docetaxel. Cancer Biol Ther 2011; 11: 204-212 [PMID: 21057205]
60. Fukumoto M, Amanuma T, Kuwahara Y, Shimura T, Suzuki M, Mori S, Kumamoto H, Saito Y, Ohkubo Y, Duan Z, Sano K, Oguchi T, Kainuma K, Usami S, Kinoshita K, Lee I, Fukumoto M. Guanine nucleotide-binding protein 1 is one of the key molecules contributing to cancer cell radioresistance. Cancer Sci 2014; 105: 1351-1359 [PMID: 25098609 DOI: 10.1111/cas.12489]
61. Li M, Mukasa A, Inda MM, Zhang J, Chin L, Cavenee W, Furnari F. Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma. J Exp Med 2011; 208: 2657-2673 [PMID: 22162832]
62. Lan Q, Wang A, Cheng Y, Mukasa A, Ma J, Hong L, Yu S, Sun L, Huang Q, Purow B, Li M. Guanylate binding protein-1 mediates EGFRvIII and promotes glioblastoma growth in vivo but not in vitro. Oncotarget 2016; 7: 9680-9691 [PMID: 26848767 DOI: 10.18632/oncotarget.7109]
63. Itsui Y, Sakamoto N, Kakinuma S, Nakagawa M, Sekine-Osajima Y, Tasaka-Fujita M, Nishimura-Sakurai Y, Suda G, Karakama Y, Mishima K, Yamamoto M, Watanabe T, Ueyama M, Funaoka Y, Azuma S, Watanabe M. Antiviral effects of the interferon-induced protein guanylate binding protein 1 and its interaction with the hepatitis C virus NS5B protein. Hepatology 2009; 50: 1727-1737 [PMID: 19821486 DOI: 10.1002/hep.23195]
64. Anderson SL, Carton JM, Lou J, Xing L, Rubin BY. Interferoninduced guanylate binding protein-1 (GBP-1) mediates an antiviral effect against vesicular stomatitis virus and encephalomyocarditis virus. Virology 1999; 256: 8-14 [PMID: 10087221]
65. Tietzel I, El-Haibi C, Carabeo RA. Human guanylate binding proteins potentiate the anti-chlamydia effects of interferon-gamma. PLoS One 2009; 4: e6499 [PMID: 19652711 DOI: 10.1371/journal. pone.0006499]
66. Pan W, Zuo X, Feng T, Shi X, Dai J. Guanylate-binding protein 1 participates in cellular antiviral response to dengue virus. Virol J 2012; 9: 292 [PMID: 23186538 DOI: 10.1186/1743-422x-9-292]
67. Zhu Z, Shi Z, Yan W, Wei J, Shao D, Deng X, Wang S, Li B, Tong G, Ma Z. Nonstructural protein 1 of influenza A virus interacts with human guanylate-binding protein 1 to antagonize antiviral activity. PLoS One 2013; 8: e55920 [PMID: 23405236 DOI: 10.1371/journal. pone.0055920]
68. Li LF, Yu J, Li Y, Wang J, Li S, Zhang L, Xia SL, Yang Q, Wang X, Yu S, Luo Y, Sun Y, Zhu Y, Munir M, Qiu HJ. Guanylate-Binding Protein 1, an Interferon-Induced GTPase, Exerts an Antiviral Activity against Classical Swine Fever Virus Depending on Its GTPase Activity. J Virol 2016; 90: 4412-4426 [PMID: 26889038 DOI: 10.1128/jvi.02718-15]
69. Krapp C, Hotter D, Gawanbacht A, McLaren PJ, Kluge SF, Stürzel CM, Mack K, Reith E, Engelhart S, Ciuffi A, Hornung V, Sauter D, Telenti A, Kirchhoff F. Guanylate Binding Protein (GBP) 5 Is an Interferon-Inducible Inhibitor of HIV-1 Infectivity. Cell Host Microbe 2016; 19: 504-514 [PMID: 26996307 DOI: 10.1016/j.chom.2016.02.019]
70. Kim BH, Shenoy AR, Kumar P, Das R, Tiwari S, MacMicking JD. A family of IFN-?-inducible 65-kD GTPases protects against bacterial infection. Science 2011; 332: 717-721 [PMID: 21551061 DOI: 10.1126/science.1201711]
71. Shenoy AR, Wellington DA, Kumar P, Kassa H, Booth CJ, Cresswell P, MacMicking JD. GBP5 promotes NLRP3 inflammasome assembly and immunity in mammals. Science 2012; 336: 481-485 [PMID: 22461501 DOI: 10.1126/science.1217141]
72. Al-Zeer MA, Al-Younes HM, Lauster D, Abu Lubad M, Meyer TF. Autophagy restricts Chlamydia trachomatis growth in human macrophages via IFNG-inducible guanylate binding proteins. Autophagy 2013; 9: 50-62 [PMID: 23086406 DOI: 10.4161/auto.22482]
73. Selleck EM, Fentress SJ, Beatty WL, Degrandi D, Pfeffer K, Virgin HW, Macmicking JD, Sibley LD. Guanylate-binding protein 1 (Gbp1) contributes to cell-autonomous immunity against Toxoplasma gondii. PLoS Pathog 2013; 9: e1003320 [PMID: 23633952 DOI: 10.1371/journal.ppat.1003320]
74. Cuadras MA, Feigelstock DA, An S, Greenberg HB. Gene expression pattern in Caco-2 cells following rotavirus infection. J Virol 2002; 76: 4467-4482 [PMID: 11932413]
75. Brodziak F, Meharg C, Blaut M, Loh G. Differences in mucosal gene expression in the colon of two inbred mouse strains after colonization with commensal gut bacteria. PLoS One 2013; 8: e72317 [PMID: 23951309 DOI: 10.1371/journal.pone.0072317]
76. Mirpuri J, Brazil JC, Berardinelli AJ, Nasr TR, Cooper K, Schnoor M, Lin PW, Parkos CA, Louis NA. Commensal Escherichia coli reduces epithelial apoptosis through IFN-alphaA-mediated induction of guanylate binding protein-1 in human and murine models of developing intestine. J Immunol 2010; 184: 7186-7195 [PMID: 20483731 DOI: 10.4049/jimmunol.0903116]